<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311050</url>
  </required_header>
  <id_info>
    <org_study_id>RAC# 2081-068</org_study_id>
    <secondary_id>RAC# 2081-068</secondary_id>
    <nct_id>NCT01311050</nct_id>
  </id_info>
  <brief_title>A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Faisal Specialist Hospital &amp; Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with
      Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with
      Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab</intervention_name>
    <description>Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Metastatic Colorectal Cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosed Metastatic Colorectal Cancer

        Exclusion Criteria:

          -  Patients with diagnosis other than Metastatic Colorectal Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shouki Bazarbashi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>KFSH &amp; RC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shouki Bazarbashi, M.D.</last_name>
    <phone>+966-1-4423949</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Kfsh &amp; Rc</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>December 11, 2011</last_update_submitted>
  <last_update_submitted_qc>December 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

